The Form 4 filing, an SEC report of insider stock trades, was filed on October 26, 2026. It lists sales from October 22 through October 26.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-22 |
| Date of Latest Transaction | 2026-10-26 |
| Buy/Sell | sell |
| Transaction Count | 6 |
| Shares Transacted | 35,643 |
| Price | $25.18 |
| Total Transaction Value | $897,456.68 |
| Insider | |
| Ticker Symbol | ADPT |
| Company | Adaptive Biotechnologies Corp |
| Insider Name | RUBINSTEIN JULIE |
| Insider Title | President and COO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 377,802 |
| Position Size Change | 8.62% |
| Filing | |
| Filing Date | 2026-10-26 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, listed with transaction code S. Julie Rubinstein, president and chief operating officer of Adaptive Biotechnologies (ADPT), reported six sale transactions.
What was the average price of the transaction?
The average sale price was $25.18 per share, rounded to the nearest cent. This average covers all six reported sales. Prices for the individual sales are not available in the transaction details.
How did this transaction affect the insider's holdings?
She sold 35,643 shares and reported 377,802 shares owned afterward. The shares sold made up 8.62% of her reported shares owned before these sales.
What's the total transaction value?
The six sales had a total value of $897,456.68. That amount covers the reported sales from October 22 through October 26, 2026.
Are there any special circumstances around this transaction?
The available details include a reference to a Rule 10b5-1 trading plan. Such plans set instructions for trades in advance. The footnote text is not available, so it is unclear which of the six sales the reference covers. The plan's start date, trade schedule and other terms are not known.
For research purposes only; not investment advice.